Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.


17 November 2021 Eosinophils in Metabolic Health and Disease

Eosinophil in Metabolic Health and Disease
17 November
9:30-11:00 AM ET

November Seminar Registration



Eosinophils restore age-related adipose tissue dysfunction and sustain physical and immune fitness in old age

Alexander Eggel, PhD
Research Group Leader
University Hospital Bern
Department of RIA

Alexander Eggel, PhD's research group at the University of Bern, Switzerland mainly focuses on the investigation of biologic mechanisms underlying both beneficial as well as pathologic type-2 immune responses. On the one hand, they are trying to get a better understanding about the development of allergies to come up with novel disease modifying treatment approaches. On the other hand, they are interested in age-related immunological changes and the possibility to manipulate regulatory functions of our immune system to systemically rejuvenate an aging mammalian organism. In both fields, theyintegrate
molecular, cellular and systemic approaches to get a holistic view of the biological mechanisms.





Eosinophils as new players in cardiovascular diseases

Dr. Konstantin Stark

Dr. Konstantin Stark is a cardiologist at the University hospital Munich (Ludwig-Maximilian-University). He is a translational researcher with clinical specialization in interventional cardiology and intensive care medicine. His research group investigates mechanisms of sterile inflammation focusing on thrombosis and atherosclerosis. In these settings, his team identified an important contribution of eosinophils by applying a translational approach involving animal models as well as human samples. 
Dr. Stark received a Starting grant of the European Research Council in 2020, where he investigates systemic inflammatory mechanisms of thrombosis. Aiming to uncover anti-inflammatory targets for prevention and therapy of cardiovascular diseases, his work is embedded in collaborative research centers in the fields of leukocytes trafficking and atherosclerosis.




Adipose Tissue resident Eosinophil and insulin Resistance: is there a human connection?

Dr. Elena De Filippis, MD PhD

Dr. Eleanna De Filippis, is an Assistant Professor of Medicine and the Associate Research Chair of the Division of Endocrinology at Mayo Clinic Arizona (MCA). Dr. De Filippis is originally from Foggia, Italy, where she completed her medical school at the University of Chieti “G. d’Annunzio”. After graduation, she moved to the USA to begin her PhD program in collaboration with the University of Texas Health Science Center in San Antonio, Tx (UTHSCSA). Upon completing her PhD, she entered the internal medicine residency at UTHSCSA. After residency, she moved to Boston, obtaining her fellowship in endocrinology, diabetes and metabolism at Harvard, at the Beth Israel Medical Deaconess Center and Joslin Diabetes Center. 
She joined MCA in 2013 as a junior faculty. At Mayo Clinic, she is an active clinical and translational investigator with primary research interests focused on obesity and insulin resistance. In her laboratory she studies the interaction between adipocytes and adipose tissue resident immune cells, and its effect on adipose tissue biology and whole-body insulin sensitivity. Her studies span from animal models to bedside. She has recently completed a KL2 grant with the NIH and the Center for Clinical and Translational Science at MCA. Her research work is supported by private foundations, internal sources at Mayo Clinic, and federal entities including the Arizona Health Department. To date, Dr. De Filippis has published over 40 original articles, editorials, and reviews in the field of obesity and insulin resistance. 
She is an active member of American Diabetes Association, Obesity Society, Obesity Medicine Association, and the Endocrine Society. 

November Seminar Registration

Corporate Advisory Council

Allakos             Amgen             AstraZeneca             GSK